Given the moderate anti-leukemic activities of mTOR blockers in preclinical AML models and in clinical trials, [59, 67] a combination of GPR132 agonist and mTOR inhibitor appears to be a potential therapeutic strategy for AML. Here, MTOR is linked to acute myeloid leukemia.